You are here

SARC023

Completed
A Phase I/II Trial of Ganetespib in Combination With the mTOR Inhibitor Sirolimus for Patients With Recurrent or Refractory Sarcomas Including Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Type of Sarcoma: 
Phase I all unresectable soft tissue or bone sarcomas and Phase II unresectable malignant peripheral nerve sheath tumor (MPNST)
Drug: 
Ganetespib and Sirolimus
Accrual Status: 
Completed
Overall Study Principal Investigator: 
AeRang Kim, MD, PhD
Pediatric Oncologist
Children’s National Medical Center

Brigitte C. Widemann, MD
Senior Investigator, Pediatric Oncology Branch
National Cancer Institute (NCI)

For more information about this trial and open sites: